MannKind Corporation (NASDAQ:MNKD) will present at upcoming conferences. Jefferies 2014 Global Healthcare Conference on June 2, 2014 at 2:30 pm (ET) in New York, New York; Goldman Sachs 35th Annual Global Healthcare Conference on June 12, 2014 at 11:20 am (PT) at the Terranea Resortin Rancho Palos Verdes, California. MannKind Corporation (NASDAQ:MNKD) weekly performance is 9.48%. On last trading day company shares ended up $8.55. Analysts mean target price for the company is $8.07. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 33.31%.
On 28 MAY Gilead Sciences, Inc. (NASDAQ:GILD) reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was up 97.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $6.19 EPS for the current fiscal year. Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 0.27% in last trading session and ended the day on $82.08. GILD Gross Margin is 77.80% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly performance is -1.88%.
On 5 MAY Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced financial results for the first quarter ended March 31, 2014. Cash, cash equivalents, and marketable securities totaled $71.6 million at March 31, 2014 compared to $82.0 million at December 31, 2013. Total operating expenses decreased to $16.1 million compared to $17.3 million for the first quarter 2013 due to decreases in personnel and contract research costs. Net cash spend was $10.4 million, compared to $14.4 million for the first quarter 2013. Net loss was $15.9 million, or $0.25 per share, compared to a net loss of $17.5 million, or $0.35 per share, for the first quarter 2013. Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares moved up 9.95% in last trading session and were closed at $2.43, while trading in range of $2.15 – $2.45. Amicus Therapeutics, Inc. (NASDAQ:FOLD) year to date (YTD) performance is 3.40%.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported ($0.17) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.17). The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $3.34 million. During the same quarter last year, the company posted ($0.09) earnings per share. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ended the last trading day at $10.22. Company weekly volatility is calculated as 7.84%and price to cash ratio as 19.55. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) showed a positive weekly performance of 18.15%.
On 15 MAY VIVUS, Inc. (NASDAQ:VVUS) announced that a poster describing results of an analysis of the association between weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV and annual concomitant medication costs will be presented at the AACE 23rd Annual Scientific & Clinical Congress at the Paris Las Vegas Hotel, Las Vegas, NV. VIVUS, Inc. (NASDAQ:VVUS) weekly performance is 10.82%. On last trading day company shares ended up $5.12. Analysts mean target price for the company is $7.33. VIVUS, Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is -2.95%.